Bladder cancer
New hope for patients progressing after prior treatment for mUCa
Obiettivo della formazione: Identify appropriate treatment options for patients progressing after prior treatment for metastatic urothelial carcinoma (UCa), a patient population who only had limited options in the past.
Specializzazione: Medical oncology, urology, clinical oncology, (radiation oncology)
Pubblico target: CME (basic, intermediate), Residents (senior)
Aggiornamento più recente: December 2023
Premessa:
Regulatory approval status of drugs limited to the metastatic UCa setting (status 20 December 2023)
CPS: combined positive score